Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control
In parallel with their development of the first synthetic gene drives – which greatly increase the chance a specific gene will be passed on to all offspring – George Church, Ph.D., and Kevin Esvelt, Ph.D., helped pioneer proactive biosafety measures to ensure that gene drives are investigated effectively and safely in confined laboratory experiments. They envision that synthetic gene drives designed using an RNA-guided gene editing system known as CRISPR-Cas9 – which works like a pair of molecular scissors to precisely cut or edit DNA – could one day be used outside of the lab to prevent transmission of deadly insect and animal-borne diseases and eradicate invasive species that threaten the ecosystem and agriculture.
Now, in a new study published in Nature Biotechnology on November 16, a team led by Church and Esvelt at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) demonstrates effective safeguarding mechanisms for working with gene drives and unveils a first-of-its-kind method for reversing the changes they spread.
“Any claim of reversibility of modern technology requires strong evidence,” said Church, who is a Wyss Core Faculty member, the Robert Winthrop Professor of Genetics at HMS, and Professor of Health Sciences and Technology at Harvard and MIT. “This is a major step in that direction for the field of synthetic biology.”
Alongside researchers on the Wyss Institute’s Synthetic Biology platform, Church and Esvelt, who is a Wyss Technology Development Fellow, have led the gene drive research community in discussions about responsible laboratory conduct and proactive confinement guidelines for the safeguarding of gene drive research. Their latest study verifies the efficacy of safeguarding protocols developed by their team, such as increased and improved physical biocontainment barriers and the introduction of so-called “molecular confinement” mechanisms which use genetic engineering to block laboratory organisms from surviving and reproducing in the highly unlikely event they ever escaped into the ecosystem.
“The gene drive research community has been actively discussing what should be done to safeguard shared ecosystems, and now we have demonstrated that the proposed safeguards work extremely well and should therefore be used by every gene drive researcher in every relevant lab organism,” said Esvelt.
CRISPR gene drives work by using sequences of RNA to guide the gene-cutting Cas9 protein to a specific target gene for editing. The molecular confinement mechanisms developed by the team prevent gene drives from functioning in the wild by manipulating these biological components. By separating the guide RNA and the Cas9 protein so that they are not encoded together in the same organism, or by inserting an artificial sequence into the targeted gene, gene drives can only be activated in lab organisms and are therefore not able to function in the wild.
“Using yeast in the lab, we also showed that a trait imposed on a population using a gene drive could be reversed,” said the paper’s first co-first author James Dicarlo, a graduate research assistant at the Wyss Institute and HMS. The team notes that using this safeguard, essentially any population-level change mediated by a gene drive could be subsequently overwritten if the need ever arose. In such a case, the originally imposed trait would be reversed and the biological “machinery” of the CRISPR gene drive system – the guide RNAs and the Cas9 protein – would remain present, albeit rendered inactive, in the DNA of organisms.
The reversibility mechanism isn’t just a useful backup to have on hand in case a gene drive ever had an unexpected side-effect; the ability to impose or reverse gene drive effects could also one day prove useful for the management of disease transmitting organisms such as mosquitoes, invasive species, and crop-destroying insects.
Although more research needs to be done in the lab before gene drives will ever potentially be ready for use outside of confined laboratory experiments, researchers now have the tools to perform those experiments safely. And in the meantime, gene drives themselves are useful lab tools for perturbing the genomes of lab organisms and unlocking new insights into the complex interplay of genes.
The Latest on: Gene drives
via Google News
The Latest on: Gene drives
- Brain Cells That Help Drive Bodily Reaction to Fear, Anxiety Identified – Neuroscience Breakthrough Could Lead to Mental Health Treatmentson January 23, 2021 at 10:51 pm
A feat of basic neuroscience co-led by UNC School of Medicine scientists, the discovery of a set of arousal-related neurons could help scientists develop better treatments for anxiety disorders, ...
- Drive-In Dust Offs: Night Of The Blood Beast (1958)on January 23, 2021 at 12:02 pm
If I was a producer, I too would have changed the title of my movie from The Creature from Galaxy 27 to Night of the Blood Beast (1958); of course, Roger Corman being that producer means there’s a ...
- AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summiton January 23, 2021 at 12:23 am
(Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at ...
- Gene Delivery Systems Market By Development, Trends, Investigation 2020 And Forecast To 2026on January 22, 2021 at 9:15 pm
Jan (Market Insight Reports) -- Global Gene Delivery Systems Market identifies major important questions and points, categorizing information ...
- Gene Therapy Market Size by Business Status 2021: Covid-19 Impact and Recovery, Growth Share, and Industry Revenue Forecast to 2026on January 19, 2021 at 6:54 pm
Final Report will add the analysis of the impact of COVID-19 on this industry." The “Gene Therapy Market” report is ...
- Gene Therapy for Rare Diseases: Strategies to Drive Operations, Upcoming Webinar Hosted by Xtalkson January 17, 2021 at 10:30 am
In this free webinar, the featured speakers will discuss the scientific, clinical, regulatory and operational complexities specific to rare disease clinical development. Attendees will learn how to ...
- Triangle’s gene therapy hub has another rising star: Atsena, targeting blindnesson January 15, 2021 at 8:40 am
Meet Atsena Therapeutics – a clinical-stage gene therapy company headquartered in Durham that's on a mission to reverse and prevent blindness.
- Gene Siskel Film Center names Rebecca Fons director of programmingon January 15, 2021 at 8:07 am
Rebecca Fons, former Chicago International Film Festival education head and Iowa City programmer, moves to Gene Siskel Film Center in key curatorial role.
- FDA, USDA still at odds regarding livestock gene-editingon January 14, 2021 at 8:40 am
NPPC offers initial comments on USDA’s rulemaking for gene-edited livestock species. In public comments earlier this week, the current Food and Drug Administration Commissioner Dr. Stephen Hahn says ...
- HTR2A Gene Changes Found Only in Progressive MS May Be New Biomarkeron January 13, 2021 at 7:53 am
Scientists have discovered epigenetic changes in a gene called HTR2A, found only in immune cells isolated from people with secondary progressive multiple sclerosis (SPMS), a study reported. These ...
via Bing News